Market Overview

UPDATE: Deutsche Bank Initiates Viropharma at Buy with PT of $37 on Under-Appreciated Pipeline

Related VPHM
Aurinia Pharma Merits Speculative Buy On M&A Appeal; Phase 3 Study Remains Paramount
US Stock Futures Signal Flat Start On Wall Street

Deutsche Bank initiated its coverage on Viropharma (NASDAQ: VPHM) with a Buy rating and a price target of $37 a share.

Deutsche Bank noted, "We see Viropharma's core drug Cinryze, for HAE, continuing to grow above street & company expectations in the US & EU. We believe competition beyond 2016 when marketing exclusivity expires will slow, but not erode growth. Finally, at these share levels we believe credit is not being assigned to the "other" marketed products Plenadren & Buccolam or the pipeline. Maribavir ph2 , US Plenadren clarity, & VP20621 interim ph2 late '12 as well as EOE ph2 data in 2013 provide upside."

Viropharma closed at $27.33 on Tuesday.

Latest Ratings for VPHM

Nov 2013Stifel NicolausDowngradesBuyHold
Nov 2013JP MorganDowngradesOverweightNeutral
Nov 2013PiperJaffrayDowngradesOverweightNeutral

View More Analyst Ratings for VPHM
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Initiation Pre-Market Outlook Analyst Ratings


Related Articles (VPHM)

View Comments and Join the Discussion!